Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
9.12.2020 12:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
“The acquisition of Labor Dr. Merk & Kollegen is strengthening our promising pipeline with diverse potential first-in-class cancer immunology and cancer cell directed therapies for patients with hard-to-treat cancer,” said Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies. We will welcome the Labor Dr. Merk & Kollegen team and look forward to jointly advancing our program in this area.”
Boehringer Ingelheim is taking cancer on by strengthening its position in cancer immunology, with a focus on cancer vaccines, oncolytic viruses, T-cell engagers, stromal modulators and myeloid cell modulators by combining its world-class, in-house research and development with that of highly innovative external companies. The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities and capacities by establishing an end-to-end fully integrated center of excellence for virus development and clinical manufacturing. It will add to a series of strategic acquisitions and collaborations over the past years, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are contributing assets that will be further developed at Labor Dr. Merk & Kollegen’s site.
Labor Dr. Merk & Kollegen is a privately-held company founded in 1971. It is headquartered in Ochsenhausen, Germany, close to Boehringer Ingelheim’s Biberach R&D site. As a center of excellence in virology, Labor Dr. Merk & Kollegen has a long track record in GLP and GMP certified biosafety testing. In recent years Labor Dr. Merk & Kollegen established its GMP-virus manufacturing facility. With around 130 highly qualified and specialized employees, the company has built considerable expertise in process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen will be integrated with all employees as a new unit into Boehringer Ingelheim’s Development organization and continue to operate at its Ochsenhausen site. A future expansion is planned.
“Following our successful strategic partnership, we are really excited to join forces with Boehringer Ingelheim,” said Dr. Ingrid Rapp, CEO at Labor Dr. Merk & Kollegen. “Boehringer Ingelheim is a truly global pharmaceutical company with excellent R&D capacities. We look forward to taking our next development step in oncology as part of this outstanding team.”
The companies did not disclose the financial terms of the deal. The transaction is subject to the approval of the competition authorities in Germany. Closing will follow thereafter.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-labor-dr-merk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005383/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply: a New Study Shows that Agentic AI will Become a Strategic Alternative to Traditional Sourcing Models for 93% of Tech Leaders10.3.2026 12:26:00 EET | Press release
Reply [EXM, STAR: REY] today announced the release of “From Code to Control: AI’s Takeover of Software Development Lifecycle”, a commissioned study conducted by Forrester Consulting. The research, which surveyed 536 IT Executives across Europe and the US, highlights the progressive transition from simple AI coding assistants to autonomous agents capable of orchestrating the entire software development lifecycle (SDLC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310922600/en/ Silicon Shoring is Reply’s delivery model designed to leverage this shift toward Agentic AI. By using the Silicon Reply multi-agent system, this methodology offers a robust alternative to traditional offshoring. The study underscores a critical turning point for software development: as traditional offshoring models struggle with hidden costs and regulatory hurdles, 93% of organisations plan to adopt Agentic AI within the next two to three years a
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel10.3.2026 12:00:00 EET | Press release
WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310966566/en/ WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel These initiatives reflect the company’s commitment to advancing women’
Spring into Smarter Home Protection: EZVIZ Launches Standout Deals for the Amazon Spring Sale10.3.2026 11:30:00 EET | Press release
As the new season brings longer days and fresh beginnings, EZVIZ is turning up the excitement with a lineup of irresistible offers during the Amazon Spring Sale. Known for delivering easy-to-use smart security products, EZVIZ is giving households the perfect opportunity to refresh their home protection with technology designed for modern living. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310567932/en/ Spring into smarter home protection: EZVIZ launches standout deals for the Amazon Spring Sale As homes open up to the energy of spring, whether welcoming guests, receiving more deliveries, or simply spending more time outdoors, this seasonal sales on Amazon offers a timely chance to upgrade everyday security. During the Spring Sale, shoppers can enjoy limited-time savings on a curated selection of EZVIZ’s smart cameras and entryway products, making it easier to safeguard front doors, gardens, and outdoor spaces while emb
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 202510.3.2026 11:00:00 EET | Press release
Ferring today published its 2025 Annual Report and Sustainability Report. The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin® (nadofaragene firadenovec-vncg). Operating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior
Quectel Unveils Versatile Pi Series SBCs to Power Developer Innovation10.3.2026 10:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of its range of Quectel Pi series of single-board computers (SBCs), designed for a broad range of industrial use cases. The portfolio currently includes three compact development platforms - the Quectel Pi M1, L1, and H1 boards - engineered for low power consumption, cost efficiency, and full-stack software support. Designed to accelerate prototyping and product development, they are well suited for embedded applications, IoT solutions, robotics projects, and edge computing deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310949640/en/ Quectel unveils versatile Pi series SBCs to power developer innovation “We’re delighted to launch the affordable, versatile, open source Quectel Pi series of SBCs to help developers of real IoT projects in areas such as home automation, robotics, sensors and edge computing to achiev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom